Literature DB >> 31145420

Tumor Mutation Burden-From Hopes to Doubts.

Alfredo Addeo1, Giuseppe L Banna2, Glen J Weiss3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31145420     DOI： 10.1001/jamaoncol.2019.0626

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  37 in total

Review 1.  The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead.

Authors:  William E Evans; Ching-Hon Pui; Jun J Yang
Journal:  Clin Pharmacol Ther       Date:  2019-11-14       Impact factor: 6.875

2.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Authors:  D J McGrail; P G Pilié; N U Rashid; L Voorwerk; M Slagter; M Kok; E Jonasch; M Khasraw; A B Heimberger; B Lim; N T Ueno; J K Litton; R Ferrarotto; J T Chang; S L Moulder; S-Y Lin
Journal:  Ann Oncol       Date:  2021-03-15       Impact factor: 32.976

3.  Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.

Authors:  A Passaro; P Mancuso; S Gandini; G Spitaleri; V Labanca; E Guerini-Rocco; M Barberis; C Catania; E Del Signore; F de Marinis; F Bertolini
Journal:  Clin Transl Oncol       Date:  2019-06-28       Impact factor: 3.405

Review 4.  Tumour burden and efficacy of immune-checkpoint inhibitors.

Authors:  Filippo G Dall'Olio; Aurélien Marabelle; Caroline Caramella; Camilo Garcia; Mihaela Aldea; Nathalie Chaput; Caroline Robert; Benjamin Besse
Journal:  Nat Rev Clin Oncol       Date:  2021-10-12       Impact factor: 66.675

5.  Correction to Conflict of Interest Disclosure.

Authors: 
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 31.777

6.  Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers.

Authors:  Hao-Xiang Wu; Zi-Xian Wang; Qi Zhao; Dong-Liang Chen; Ming-Ming He; Lu-Ping Yang; Ying-Nan Wang; Ying Jin; Chao Ren; Hui-Yan Luo; Zhi-Qiang Wang; Feng Wang
Journal:  Ann Transl Med       Date:  2019-11

7.  Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.

Authors:  Daniel V Araujo; Ao Wang; Dax Torti; Alberto Leon; Kayla Marsh; Aoife McCarthy; Hal Berman; Anna Spreafico; Aaron R Hansen; Albiruni-Abdul Razak; Philippe L Bedard; Lisa Wang; Eric Plackmann; Helen Chow; Hua Bao; Xue Wu; Trevor J Pugh; Lillian L Siu
Journal:  JNCI Cancer Spectr       Date:  2021-01-23

8.  Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.

Authors:  Junyu Long; Dongxu Wang; Xu Yang; Anqiang Wang; Yu Lin; Mingjun Zheng; Haohai Zhang; Xinting Sang; Hanping Wang; Ke Hu; Haitao Zhao
Journal:  BMC Med       Date:  2021-07-21       Impact factor: 8.775

Review 9.  Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.

Authors:  Aaron C Tan; Stephen J Bagley; Patrick Y Wen; Michael Lim; Michael Platten; Howard Colman; David M Ashley; Wolfgang Wick; Susan M Chang; Evanthia Galanis; Alireza Mansouri; Simon Khagi; Minesh P Mehta; Amy B Heimberger; Vinay K Puduvalli; David A Reardon; Solmaz Sahebjam; John Simes; Scott J Antonia; Don Berry; Mustafa Khasraw
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

10.  Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.

Authors:  Xinan Wang; Biagio Ricciuti; Joao V Alessi; Tom Nguyen; Mark M Awad; Xihong Lin; Bruce E Johnson; David C Christiani
Journal:  J Natl Cancer Inst       Date:  2021-06-11       Impact factor: 11.816
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.